Quote | Clene Inc. (NASDAQ:CLNN)
Last: | $0.369 |
---|---|
Change Percent: | -2.53% |
Open: | $0.36 |
Close: | $0.369 |
High: | $0.3731 |
Low: | $0.352 |
Volume: | 219,576 |
Last Trade Date Time: | 06/27/2024 03:00:00 am |
News | Clene Inc. (NASDAQ:CLNN)
Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,...
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) ...
Message Board Posts | Clene Inc. (NASDAQ:CLNN)
Subject | By | Source | When |
---|---|---|---|
$CLNN Looks pretty positive | tw0122 | investorshub | 05/08/2023 6:20:21 PM |
we got news | 81vette | investorshub | 05/03/2023 7:49:35 AM |
$CLNN Have a look at this | harry crumb | investorshub | 04/28/2023 8:55:42 PM |
$CLNN bulls and bears | 81vette | investorshub | 04/24/2023 1:44:10 AM |
$CLNN The gaining | skichic | investorshub | 04/23/2023 10:49:34 AM |
News, Short Squeeze, Breakout and More Instantly...
Clene Inc. Company Name:
CLNN Stock Symbol:
NASDAQ Market:
Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,...
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) ...
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal fu...